Acrivon Therapeutics, Inc. Financing Cash Flow
Acrivon Therapeutics, Inc. (ACRV) reported Financing Cash Flow of $7.24 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-12
- Acrivon Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $7.27M.
- Acrivon Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was -$33.00K.
- Acrivon Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was -$192.00K.
- Acrivon Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was -$117.00K.
- Acrivon Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2025 was -$749.00K, a 100.62% decline from fiscal 2024.
- Acrivon Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2024 was $121.03M.
- Acrivon Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2023 was -$1.55M, a 101.53% decline from fiscal 2022.
- Acrivon Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2022 was $101.71M, a 9.37% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $7.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $7.24M 10-Q · filed 2026-08-12 | $7.04M derived: sum of 3 quarters · filed 2026-08-12 | $6.93M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | -$33.00K 10-Q · filed 2026-05-13 | -$225.00K derived: sum of 2 quarters · filed 2026-05-13 | -$342.00K derived: sum of 3 quarters · filed 2026-05-13 | -$439.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | -$192.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$309.00K derived: sum of 2 quarters · filed 2026-03-19 | -$406.00K derived: sum of 3 quarters · filed 2026-08-12 | -$749.00K 10-K · filed 2026-03-19 |
| 2025-09-30 | -$117.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$214.00K derived: sum of 2 quarters · filed 2026-08-12 | -$557.00K 10-Q · filed 2025-11-13 | -$1.20M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | -$97.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$440.00K 10-Q · filed 2026-08-12 | -$1.09M derived: sum of 3 quarters · filed 2026-08-12 | -$2.59M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | -$343.00K 10-Q · filed 2026-05-13 | -$990.00K derived: sum of 2 quarters · filed 2026-05-13 | -$2.49M derived: sum of 3 quarters · filed 2026-05-13 | $120.86M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | -$647.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$2.15M derived: sum of 2 quarters · filed 2026-03-19 | $121.20M derived: sum of 3 quarters · filed 2026-03-19 | $121.03M 10-K · filed 2026-03-19 |
| 2024-09-30 | -$1.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $121.85M derived: sum of 2 quarters · filed 2025-11-13 | $121.67M 10-Q · filed 2025-11-13 | $119.66M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $123.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $123.18M 10-Q · filed 2025-08-13 | $121.17M derived: sum of 3 quarters · filed 2025-08-13 | $121.25M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | -$172.00K 10-Q · filed 2025-05-14 | -$2.18M derived: sum of 2 quarters · filed 2025-05-14 | -$2.10M derived: sum of 3 quarters · filed 2025-05-14 | |
| 2023-12-31 | -$2.01M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | -$1.93M derived: sum of 2 quarters · filed 2025-03-27 | -$1.55M 10-K · filed 2025-03-27 | |
| 2023-09-30 | $78.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $457.00K 10-Q · filed 2024-11-13 | ||
| 2023-06-30 | $379.00K 10-Q · filed 2024-08-13 | |||
| 2022-12-31 | $101.86M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $101.72M derived: sum of 2 quarters · filed 2024-03-28 | $101.71M 10-K · filed 2024-03-28 | |
| 2022-09-30 | -$140.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$151.00K 10-Q · filed 2023-11-09 | ||
| 2022-06-30 | -$11.00K 10-Q · filed 2023-08-11 | |||
| 2021-12-31 | $99.75M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | $112.22M 10-K · filed 2023-03-28 | ||
| 2021-09-30 | $12.47M 10-Q · filed 2022-12-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rallybio Corp (RLYB) | United States | $0.089B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B |